DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Services

Food and Drug Administration
Rockville, MD 20857

NDA 19-885/S-018

Pfizer Inc.
Attention: Mr. James A. Parker, Jr.
235 East 42nd Street
New York, NY 10017

Dear Mr. Parker:

Please refer to your supplemental new drug application dated August 5, 1999 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Accupril (quinapril hydrochloride) Tablets.

We acknowledge receipt of your submission dated March 27, 2001.

This supplemental new drug application provides for final printed labeling revised as follows:

1. A **PRECAUTIONS/Geriatric Use** subsection has been added as follows:

> Clinical studies of ACCUPRIL did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.
>
> This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
>
> Elderly patients exhibited increased area under the plasma concentration time curve and peak levels for quinaprilat compared to values observed in younger patients; this appeared to relate to decreased renal function rather than to age itself.

2. Edema and arthralgia have been added under **ADVERSE REACTIONS/Other**, as follows:

> **Other:** amblyopia, edema, arthralgia, pharyngitis, *agranulocytosis, hepatitis, thrombocytopenia*

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the final printed labeling included in your March 27, 2001 submission.

Accordingly, the supplemental application is approved effective on the date of this letter.

If you have any questions, please contact:

Ms. Sandra Birdsong
Regulatory Health Project Manager
(301) 594-5334

Sincerely,

{See appended electronic signature page}

Raymond J. Lipicky, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research